Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Thomas Lander"'
Autor:
Ingmar Hoerr, Alexander Knuth, Alfred Zippelius, Tanja Strack, Jochen Probst, Ulrike Gnad-Vogt, Florian Von Der Muelbe, Djordje Atanackovic, Andreas Gröschel, Frank Mayer, Michael Thomas, Volker Wiegand, Henoch S. Hong, Anke Muth, Andreas Schröder, Lotta von Boehmer, Folker Schneller, Karl-Josef Kallen, Martin Sebastian, Thomas Lander, Jan Stöhlmacher, Birgit Scheel, Martin Reck, Sven D. Koch, Mariola Fotin-Mleczek, Helga Bernhard
Publikováno v:
Cancer immunology, immunotherapy : CII. 68(5)
CV9201 is an RNActive®-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::831ce155a01de8ed1f4bc942ea483d77
https://pubmed.ncbi.nlm.nih.gov/30770959
https://pubmed.ncbi.nlm.nih.gov/30770959
Autor:
Christian Hampel, Kurt Miller, Giorgio Parmiani, Florian Von Der MüLBE, Gerd Rippin, Mariola Fotin-Mleczek, Tobias Maurer, Dieter Jocham, Lutz Trojan, Arnulf Stenzl, Thomas Lander, Hubert Kübler, Frank vom Dorp, Jochen Probst, Ulrike Gnad-Vogt, Ingmar Hoerr, Steffen Wedel, Wolfgang Schultze-Seemann, Karl-Josef Kallen, Birgit Scheel
Publikováno v:
Journal for Immunotherapy of Cancer
Background CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety and immunogenicity of CV9103 in patients with advanced castration-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63de357bf676fdec0e5f85b051ff49ab
https://www.ncbi.nlm.nih.gov/pubmed/26082837
https://www.ncbi.nlm.nih.gov/pubmed/26082837
Autor:
Dieter Jocham, L. Pilla, A. Stenzl, Susan Feyerabend, K. Kurt, Christian Hampel, W. Schultze-Seemann, Ulrike Gnad-Vogt, B. Birgit, Thomas Lander, Martin Schostak, S. Wedel, K. Hiller, Hubert Kübler, G. Parmiani, Karl-Josef Kallen, Lutz Trojan, M. Sommerauer, F. Vom Dorp, M. Reindl, Ursula Steiner, Tobias Maurer
Publikováno v:
European Urology Supplements. 11:189
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4444724a2f795c715f874a30260ac4a2
https://doi.org/10.1016/s1569-9056(13)60380-2
https://doi.org/10.1016/s1569-9056(13)60380-2
Autor:
Volker Wiegand, Gerd Rippin, Sven D. Koch, Karl-Josef Kallen, Eray Goekkurt, Djordje Atanackovic, Alexander Knuth, Thomas Lander, Frank Mayer, Ulrike Gnad-Vogt, Andreas Groeschel, Martin Sebastian, Jan Stoehlmacher-Williams, Alfred Zippelius, Birgit Scheel, Michael Thomas, Martin Reck, Lotta von Boehmer, Folker Schneller, Helga Bernhard
Publikováno v:
Journal of Clinical Oncology. 30:2573-2573
2573^ Background: Vaccination with mRNA is a novel technology in cancer immunotherapy. CV9201 consists of self-adjuvanted mRNA molecules (RNActive) coding for five non small cell lung cancer (NSCLC)-associated tumor antigens (MAGE-C1, MAGE-C2, NY-ESO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a87a8cb9949cffdafe40f584b8e9d42
https://doi.org/10.1200/jco.2012.30.15_suppl.2573
https://doi.org/10.1200/jco.2012.30.15_suppl.2573
Autor:
K. Hiller, Birgit Scheel, Tobias Maurer, A. Stenzl, Christian Hampel, W. Schultze-Seemann, S. Wedel, Lutz Trojan, Karl-Josef Kallen, F. vom Dorp, Thomas Lander, Hubert Kübler, Susan Feyerabend, Dieter Jocham, Ursula Steiner, M. Sommerauer, Martin Schostak, Kurt Miller, L. Pilla, G. Viatali
Publikováno v:
Journal of Clinical Oncology. 29:4535-4535
4535 Background: CV9103 is a prostate cancer (PCA) vaccine that contains the four antigens PSA (prostate specific antigen), PSCA, PSMA and STEAP1 as self-adjuvanted full-length mRNAs. Methods: Patients with castrate resistant PCA with rising PSA and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::827bb11ef6d027466616d46bb40ceff2
https://doi.org/10.1200/jco.2011.29.15_suppl.4535
https://doi.org/10.1200/jco.2011.29.15_suppl.4535
Autor:
A. Groeschel, Djordje Atanackovic, Sven D. Koch, R. Bals, Jan Stoehlmacher, S. Schmidt, Alfred Zippelius, Birgit Scheel, Helga Bernhard, Alexander Knuth, Michael Thomas, Thomas Lander, Martin Sebastian, L. von Boehmer, Eray Goekkurt, Frank Mayer, Karl-Josef Kallen, Folker Schneller, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 29:2584-2584
2584 Background: CV9201 is a therapeutic cancer vaccine for non small cell lung cancer (NSCLC) based on a novel vaccination technology using self-adjuvanted mRNA molecules. It comprises five mRNAs encoding NSCLC associated tumor antigens (NY-ESO1, Ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fff89142dd9fd74c1428809e5c1109ce
https://doi.org/10.1200/jco.2011.29.15_suppl.2584
https://doi.org/10.1200/jco.2011.29.15_suppl.2584
Publikováno v:
Diabetes. 38:1557-1566
Flow cytometry was recently introduced for the detection of antibodies in human serum to a cultured insulin-secreting rat insulinoma cell line (RINm5F) to investigate humoral immune reactivity in newly diagnosed type I (insulin-dependent) diabetic pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161a5342d40559610be00589da042cc1
https://doi.org/10.2337/diabetes.38.12.1557
https://doi.org/10.2337/diabetes.38.12.1557